Endometrial intraepithelial neoplasia (EIN)

Last medical review:

A precancerous condition of the uterus is when there are changes to uterine cells that make them more likely to develop into cancer. It's not yet cancer. But if it isn't treated, there is a chance that these changes will become uterine cancer.

Endometrial intraepithelial neoplasia (EIN) is a precancerous condition in which the lining of the uterus (endometrium) becomes thick. It happens when abnormal endometrial cells grow. EIN may also be called atypical endometrial hyperplasia.

If you have EIN, there is an increased chance it will turn into endometrial carcinoma, so treatment is needed.

Risks

The main risk that increases your chance of developing EIN is when female hormones (estrogen and progesterone) are out of balance. Several things can cause female hormone changes, such as during menopause or taking drugs that change your hormone levels.

Having obesity and being over 60 years old can also increase the chance of developing EIN.

Signs and symptoms

Abnormal vaginal bleeding is the main sign of EIN. There may be vaginal discharge also, but it’s less common.

Diagnosis

If you have symptoms or your doctor thinks you might have EIN, you will be sent for tests. Tests used to diagnose EIN include:

  • a biopsy of the endometrium
  • dilation and curettage (D&C)
  • cell and tissue studies to look for genetic changes in the cells

Because EIN can turn into cancer, doctors will find out if there is endometrial carcinoma present before planning treatment.

Find out more about diagnosis of uterine cancer.

Treatments

The main treatment for EIN is a hysterectomy. If you have EIN and want to be pregnant in the future, you may be offered hormone therapy with progestin instead of surgery.

Expert review and references

  • Berek JS, Matias-Guiu X, Creutzberg C, et al. FIGO staging of endometrial cancer: 2023. International Journal of Gynecology and Obstetrics. 2023: 162:383–394.
  • Campos SM, del Carmen MG. Therapy for endometrial cancer: radiation, chemotherapy, targeted, immunotherapy and other new and novel agents. Chi D, Berchuck A, Dizon DS, Yashar CM. Principles and Practice of Gynecologic Oncology. 8th ed. Philadelphia, PA: Wolters Kluwer Health; 2025: 5.6:159–179.
  • Hacker NF, Friedlander ML. Uterine cancer. Berek J, Hacker NF. Berek and Hacker's Gynecologic Oncology. 7th ed. Philadelphia, PA: Wolters Kluwer; 2021: 10:371–420.

Your trusted source for accurate cancer information

With support from readers like you, we can continue to provide the highest quality cancer information for over 100 types of cancer.

We’re here to ensure easy access to accurate cancer information for you and the millions of people who visit this website every year. But we can’t do it alone.

Every donation helps fund reliable cancer information, compassionate support services and the most promising research. Please give today because every contribution counts. Thank you.

Medical disclaimer

The information that the Canadian Cancer Society provides does not replace your relationship with your doctor. The information is for your general use, so be sure to talk to a qualified healthcare professional before making medical decisions or if you have questions about your health.

We do our best to make sure that the information we provide is accurate and reliable but cannot guarantee that it is error-free or complete.

The Canadian Cancer Society is not responsible for the quality of the information or services provided by other organizations and mentioned on cancer.ca, nor do we endorse any service, product, treatment or therapy.


1-888-939-3333 | cancer.ca | © 2025 Canadian Cancer Society